Teva Taps UCB’s Respiratory Expertise To Promote ProAir HFA In The U.S.
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal comes as Teva seeks to capture remaining market share from CFC-containing albuterol products, which must be discontinued by year-end, firm tells "The Pink Sheet" DAILY.
You may also be interested in...
CFC-Containing Albuterol Inhalers To Be Removed By 2009
FDA's final rule sets a deadline one year earlier than the latest possible date suggested in the proposed rule. Manufacturers have said that once a phase-out date was set they could build sufficient supply of ozone-friendly albuterol product within 18 months.
Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.
MADIT-CRT Data Support Expanded Cardiac Resynchronization Market
The results show that cardiac resynchronization defibrillators "slow the progression of heart failure in asymptomatic and mildly symptomatic patients," potentially expanding the market by $600 million.